updat model iqvia follow fourth-quart earn releas
thursday morn quarter result impress better-than-expect
revenu two three segment improv ebitda margin initi guidanc
better expect revenu ebitda line view result
encourag start earn season broader pharma outsourc servic
group larg small biopharma compani seek drive improv effici
across manufactur sale market
iqv fourth-quart result expect million top line
bottom line book well expectationsund
quarterli book-to-bil ratio time versu estim net award
roughli year-ago level metric doubl
would expect perhap importantli lag metric organ
revenu growth also improv solut versu estim
technolog analyt solut versu estim illustr exhibit
iqv consolid organ revenu growth best seen sinc
merger complet indic compani longer lose share cro space
increas revenu estim million billion
total organ constant-curr increas ep estim
expect underli organ growth technolog
analyt solut segment previou estim
 solut segment expect organ revenu growth step compar
previous higher growth ta particular good news
margin leverag well sinc profit segment thu remain
quit comfort continu gener midteen ep growth maintain
outperform rate view current rel valuat reason despit
iqvia integr inform technology-en healthcar servic provid annual revenu base
approach billion form merger quintil im health compani employ
roughli employe oper countri compani world lead provid
pharmaceut sale prescript data leader outsourc drug develop commerci
pleas refer import disclosur page analyst certif page
william blair affili seek busi compani cover research report
result investor awar firm may conflict interest could affect object
report report intend provid person invest advic opinion recommend
herein take account individu client circumst object need intend
recommend particular secur financi instrument strategi particular client recipi
report must make independ decis regard secur financi instrument mention
return equiti ttm
exhibit iqvia consolid organ growth present
segment observ expect
technolog analyt solut increas bit organ constant-curr basi quarter
compar target total revenu segment beat model million driven mainli sever
smaller acquisit ad percentag point growth manag commentari suggest better
sale momentum continu given larg number pend opportun win new mandat
orchestr custom engag oce platform compani roll integr suit clinic
technolog applic year could help extend better growth
project roughli organ growth includ acquisit benefit aggreg estim report
growth segment previous
 solut increas organ constant-curr basi quarterwel target
compani book-to-bil ratio quarter ratio year-over-year backlog growth
quarter give us addit comfort cro gain share miss piec
stori better win translat better revenu growthuntil quarter organ growth
manag say succeed improv revenu growth end year two post-
merger one year ahead schedul fourth quarter strong book suggest higher pace
revenu growth abl carri well expect organ growth
iqvia charl river outperform commentari week encourag sign demand trend
remain quit good drug develop outsourc next data point cro demand come icon iclr
outperform report next wednesday
contract sale medic solut decreas constant-curr basi fourth quarter
improv compar double-digit declin past three quarter result essenti match
expect manag guidanc busi flat next year better declin target
project flat sale year slight return growth syneo health outperform also better
commentari commerci busi last month indic long suffer part pharma outsourc
landscap may improv thank quicker pace fda approv
increas revenu estim million billion increas ep
estim major driver revenu chang million organ sale
technolog analyt solut solut segment lower ebitda margin
expect basi point howev also increas interest expens assumpt result ep
valuat stock thought
iqvia trade time updat estim essenti line cro group
averag multipl time maintain outperform rate given encourag sign revenu
acceler updat model iqvia follow exhibit
xxsourc compani report william blair william blair
exhibit updat iqvia hold incom statement summari
profit gener administr expens amort incom includ option beg incom expens tax investe non-controlling interests/minor hedg incom tax non control item net incom excl non-recurring item incl option beg averag share outstand averag share outstand analysi gross rate revenu begin excl foreign exchang effect pro forma beg organ pro forma beg incom excl non-recur excl non-recur item incl blair compani estimatesourc compani report william blair compani llc estim import disclosur
